RAMIPRIL-2.5 CAPSULE
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
27-01-2016
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
RAMIPRIL
Fáanlegur frá:
SIVEM PHARMACEUTICALS ULC
ATC númer:
C09AA05
INN (Alþjóðlegt nafn):
RAMIPRIL
Skammtar:
2.5MG
Lyfjaform:
CAPSULE
Samsetning:
RAMIPRIL 2.5MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100/500
Gerð lyfseðils:
Prescription
Lækningarsvæði:
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Vörulýsing:
Active ingredient group (AIG) number: 0122858004; AHFS:
Leyfisstaða:
CANCELLED POST MARKET
Leyfisdagur:
2016-06-29
Vara einkenni
1
PRODUCT MONOGRAPH
PR
RAMIPRIL-2.5
PR
RAMIPRIL-5
PR
RAMIPRIL-10
RAMIPRIL CAPSULES, MANUFACTURER’S STANDARD
2.5 MG, 5.0 MG AND 10.0 MG
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
SIVEM PHARMACEUTICALS ULC
4705 DOBRIN STREET
SAINT-LAURENT, QUEBEC
DATE OF PREPARATION:
H4R 2P7
JANUARY 12, 2016
CONTROL NO.: 190207
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
.......................................................................................................
10
DRUG INTERACTIONS
.......................................................................................................
15
DOSAGE AND ADMINISTRATION
...................................................................................
17
OVERDOSAGE
......................................................................................................................
23
ACTION AND CLINICAL
PHARMACOLOGY..................................................................
18
STORAGE AND STABILITY
...............................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 26
PART II: SCIENTIFIC INFORMATION
.............................................................................
23
PHARMACEUTICAL INFORMATION
...............................................................................
23
CLINICAL TRIALS
.........................................................................................................
Lestu allt skjalið
